Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New injection offers hope for men with chronic groin pain

NCT ID NCT05707208

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called ST-01, given as a shot into the spermatic cord every 28 days, to see if it safely reduces chronic scrotal pain better than standard lidocaine. 63 men with pain lasting over 3 months took part. The main goal was to measure pain changes using a 0-10 scale over 56 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

63 people

The number who actually took part.

Started

Mar 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult (≥ 19 years) male 2. Unilateral or bilateral scrotal pain lasting \> 3 months 3. Have nociceptive scrotal pain 4. Average daily maximum scrotal pain score over 7 days ≥ 4 on the 0-10 NRS (Appendix 2). Participants with bilateral scrotal pain must be able to distinguish one side with pain score ≥ 4 and the opposite side must have a maximum scrotal pain score of ≤ 3.0 at baseline. 5. Positive response to test spermatic cord block with 1% lidocaine (Lidocaine Hydrochloride Injection, USP, 1%, 10 mg/mL), defined as a decrease in pain score of at least 2 within 1 hour of injection 6. Baseline blood levels without clinically significant abnormalities including liver function tests (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], gamma-glutamyl transferase \[GGT\], and alkaline phosphatase \[ALP\]) no greater than 50% above the upper limit of normal 7. If sexually active, is willing to use adequate birth control methods to prevent pregnancy over the course of the study Exclusion Criteria: 1. Negative response to test spermatic cord block, defined as absence of a decrease in pain score of at least 2 within an hour of injection 2. Other pain generator site with NRS pain score ≥ 4 that interferes with evaluation of scrotal pain 3. History of allergic reaction to lidocaine or any component of ST-01 4. Any contraindication to local anesthesia with lidocaine (e.g., known hypersensitivity to anesthetics of the amide type; hypokalemia, complete heart block, anticoagulants (aspirin permitted), antiarrhythmic medication.) 5. Active infection involving the urinary tract or scrotum 6. Inability to give consent 7. Inability to follow up according to the protocol 8. Negative response to previous spermatic cord block 9. Any other condition that the investigator believes may interfere with the safety of the participant, study conduct, or interpretation of the data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jonathan Giddens Medicine Professional Corporation

    Brampton, Ontario, L6T 4S5, Canada

  • Kelowna General Hospital Clinical Research Department

    Kelowna, British Columbia, V1Y 1T2, Canada

  • Men's Health Clinic Manitoba

    Winnipeg, Manitoba, R3P 2S8, Canada

  • Mount Sinai Hospital - Men's Health Institute

    Toronto, Ontario, M5T 3L9, Canada

  • Prostate Cancer Centre - Rockyview Hospital

    Calgary, Alberta, T2V 1P9, Canada

  • THEO Medical

    Montreal, Quebec, H3M 1L3, Canada

  • The Fe/Male Health Centre

    Oakville, Ontario, L6H 3P1, Canada

  • Vancouver Prostate Centre

    Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.